 BURBANK, Calif., Oct. 12, 2021 GLOBE NEWSWIRE -- via NewMediaWire Medolife Rx, Inc. Medolife, a global integrated biopharmaceutical company with RD, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. OTCQB: QNTA, announced today results from a study on its patented polarization methodology that compared the effectiveness of generic ibuprofen, a well-known pain relief drug that works by lowering inflammation by inhibiting the cyclooxygenase-2 COX-2 enzymes activity in the body, versus polarized ibuprofen in inhibition of COX-2 activity in humans. The results showed that polarized ibuprofen was 257 more effective in inhibiting COX-2, which is expressed in inflammation and pain in humans. The result further solidifies the potential applications of polarization on the healthcare industry as a whole, whereas the therapeutic efficacy of active pharmaceutical ingredients APIs can be increased through the process, and dosage can be decreased, resulting in fewer side effects and potential damage to the liver. 